Skip to content

Sections
- Health
- Pharma
- Biotech
- Hospitals
- Politics
- In the Lab
- First Opinion
- Gut Check
- The Watchdogs
Topics
Multimedia
Popular
STAT Plus

Job Board
About Us

Newsletters
My Account
- Settings
- Log Out

Newsletters
My Account
- Settings
- Log Out

Patents

Pharmalot

The U.S. would pay an extra $10.7 billion without generic Allergan drug

By Ed Silverman

Pharmalot

Lawmakers want probe into Allergan patent deal with Mohawk tribe

By Ed Silverman

advertisement

Pharmalot

Allergan pays Mohawk tribe in a gambit to protect key patents

By Ed Silverman

advertisement

Pharmalot

AIDS activists urge N.Y. attorney general to probe Gilead for antitrust violations

By Ed Silverman

Pharmalot

Chilean lawmakers seek compulsory licenses for hepatitis and cancer drugs

By Ed Silverman

Pharmalot

Lilly loses a heated patent row with the Canadian government

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Trump nominee for CMS won’t say whether Medicare should negotiate drug prices

By Ed Silverman

advertisement

Pharmalot

Pharma trade group urges US trade rep to take action against Colombia

By Ed Silverman

advertisement

Pharmalot

Pharmalot, Pharmalittle: Shkreli talk at Harvard elicits a fire alarm and jeers

By Ed Silverman

Pharmalot

Gilead faces fresh patent challenges over hepatitis C drugs in India

By Ed Silverman

Pharmalot

Is it in the public’s interest to have two similar cholesterol drugs on the market?

By Ed Silverman

Pharmalot

European regulator amends some Gilead hep C patent claims

By Ed Silverman

Signal Podcast

Episode 16: To make big profits, drug companies turn to monopoly shenanigans

By Luke Timmerman and Meg Tirrell

First Opinion

Clinton’s proposed ban on pay-for-delay deals would do little to lower drug prices

By Farasat A.S. Bokhari

In the Lab

In CRISPR patent fight, geneticist George Church may be called to testify

By Sharon Begley

Pharmalot

University of Minnesota sues Gilead for infringing on hepatitis C patents

By Ed Silverman

In the Lab

Lies, damn lies, and CRISPR: the legal battle escalates

By Sharon Begley

Exclusive

CRISPR patent fight: The legal bills are soaring

By Sharon Begley

Pharmalot

AbbVie and Amgen lock horns in the latest squabble over biosimilars

By Ed Silverman

Pharmalot

Gilead defeats AIDS activists who claimed the company manipulated patents

By Ed Silverman

Biotech

A lucrative wrinkle in the CRISPR patent fight

By Damian Garde

Politics

Supreme Court’s ruling in patent case a blow to drug industry

By Dylan Scott

Pharmalot

Bernie Sanders accuses US Trade Rep of intimidating Colombia over Novartis patent

By Ed Silverman

Pharmalot

House Democrats blast US Trade Rep for pressuring Colombia over Novartis patent

By Ed Silverman

Pharmalot

India’s new patent policy spurs debate over implications for pharma

By Ed Silverman

Pharmalot

Colombia to Novartis: Lower the price of your cancer drug, or else

By Ed Silverman

Pharmalot

Colombian health minister is warned not to sidestep Novartis patent

By Ed Silverman

Pharmalot

US pressures Colombia over plan to sidestep patent for a Novartis drug

By Ed Silverman

Pharmalot

Gilead gets a big win as India upholds a Sovaldi patent, after all

By Ed Silverman

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

Industry

Leave this field empty if you're human:

Sign up for our morning rounds newsletter

Leave this field empty if you're human:

Reporting from the frontiers of health and medicine

About Us
Contact Us
The STAT Team
STAT Wunderkinds
Awards for STAT
Work at STAT
Job Board
Advertise

Privacy
Comment Policy
Terms

© 2017 STAT

X